UBS Group’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $13.7M | Sell |
170,600
-37,400
| -18% | -$3.08M | ﹤0.01% | 3015 |
|
|
2025
Q4 | $17.7M | Buy |
208,000
+48,400
| +30% | +$3.97M | ﹤0.01% | 2699 |
|
|
2025
Q3 | $12.4M | Buy |
159,600
+138,300
| +649% | +$10.8M | ﹤0.01% | 3064 |
|
|
2025
Q2 | $1.67M | Buy |
+21,300
| New | +$1.59M | ﹤0.01% | 4997 |
|
|
2025
Q1 | – | Sell |
-10,000
| Closed | -$740K | – | 10351 |
|
|
2024
Q4 | $740K | Hold |
10,000
| – | – | ﹤0.01% | 5551 |
|
|
2024
Q3 | $660K | Hold |
10,000
| – | – | ﹤0.01% | 5007 |
|
|
2024
Q2 | $924K | Buy |
+10,000
| New | +$886K | ﹤0.01% | 4487 |
|
|
2023
Q4 | – | Sell |
-62,600
| Closed | -$4.34M | – | 9460 |
|
|
2023
Q3 | $4.34M | Buy |
62,600
+30,000
| +92% | +$2.41M | ﹤0.01% | 2712 |
|
|
2023
Q2 | $3.08M | Buy |
+32,600
| New | +$2.83M | ﹤0.01% | 3079 |
|
|
2023
Q1 | – | Sell |
-300
| Closed | -$22.4K | – | 9791 |
|
|
2022
Q4 | $22.4K | Buy |
+300
| New | +$23.1K | ﹤0.01% | 7540 |
|
|
2022
Q2 | – | Sell |
-30,400
| Closed | -$3.58M | – | 10475 |
|
|
2022
Q1 | $3.58M | Buy |
30,400
+30,200
| +15,100% | +$3.39M | ﹤0.01% | 2880 |
|
|
2021
Q4 | $26K | Sell |
200
-100
| -33% | -$11.7K | ﹤0.01% | 7532 |
|
|
2021
Q3 | $34K | Hold |
300
| – | – | ﹤0.01% | 6639 |
|
|
2021
Q2 | $31K | Hold |
300
| – | – | ﹤0.01% | 6881 |
|
|
2021
Q1 | $25K | Hold |
300
| – | – | ﹤0.01% | 7167 |
|
|
2020
Q4 | $27K | Buy |
+300
| New | +$24.9K | ﹤0.01% | 6719 |
|
|
2020
Q2 | – | Sell |
-18,300
| Closed | -$1.15M | – | 8042 |
|
|
2020
Q1 | $1.15M | Buy |
+18,300
| New | +$1.32M | ﹤0.01% | 3238 |
|
|
2019
Q4 | – | Sell |
-600
| Closed | -$44K | – | 8180 |
|
|
2019
Q3 | $44K | Buy |
600
+300
| +100% | +$21.1K | ﹤0.01% | 6268 |
|
|
2019
Q2 | $18K | Sell |
300
-6,000
| -95% | -$363K | ﹤0.01% | 6685 |
|
|
2019
Q1 | $402K | Buy |
+6,300
| New | +$360K | ﹤0.01% | 4188 |
|
|
2018
Q4 | – | Sell |
-4,800
| Closed | -$278K | – | 8098 |
|
|
2018
Q3 | $278K | Buy |
4,800
+300
| +7% | +$14.7K | ﹤0.01% | 4812 |
|
|
2018
Q2 | $218K | Buy |
+4,500
| New | +$210K | ﹤0.01% | 4880 |
|
|
2018
Q1 | – | Sell |
-9,000
| Closed | -$338K | – | 7908 |
|
|
2017
Q4 | $338K | Sell |
9,000
-600
| -6% | -$22K | ﹤0.01% | 4565 |
|
|
2017
Q3 | $350K | Sell |
9,600
-2,400
| -20% | -$91.5K | ﹤0.01% | 4481 |
|
|
2017
Q2 | $473K | Buy |
+12,000
| New | +$438K | ﹤0.01% | 4149 |
|
|
2016
Q1 | – | Sell |
-42,567
| Closed | -$1.12M | – | 7779 |
|
|
2015
Q4 | $1.12M | Sell |
42,567
-3
| -0% | -$78 | ﹤0.01% | 3319 |
|
|
2015
Q3 | $1.01M | Buy |
42,570
+22,770
| +115% | +$550K | ﹤0.01% | 3349 |
|
|
2015
Q2 | $470K | Buy |
+19,800
| New | +$447K | ﹤0.01% | 4178 |
|
|
2015
Q1 | – | Sell |
-4,200
| Closed | -$89K | – | 8960 |
|
|
2014
Q4 | $89K | Buy |
+4,200
| New | +$84.4K | ﹤0.01% | 5812 |
|
Other funds holding EW
VCM
VPM
UBS Group's EW Position: Q1 2026 in Review
UBS Group increased its Edwards Lifesciences (EW) stake by 57% in Q1 2026, buying an estimated $76.8M and bringing the position to 2,561,776 shares worth $205M. The position accounts for 0.03% of the portfolio, ranked #605.
UBS Group first reported a position in EW in Q4 2014 and has held it in 46 quarters since. The position peaked at $371M in Q4 2021. 1,285 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- UBS Group held 2,561,776 shares of Edwards Lifesciences worth $205M as of Q1 2026.
- UBS Group bought 931,016 Edwards Lifesciences shares in Q1 2026, an estimated $76.8M.
- Edwards Lifesciences made up 0.03% of UBS Group's portfolio in Q1 2026, its #605 holding.
- UBS Group first reported a position in Edwards Lifesciences in Q4 2014 and has held it in 46 quarters since.
- UBS Group's Edwards Lifesciences position peaked at $371M in Q4 2021.
- 1,285 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.